December 18, 2017

Magseed/Lesion Localisation

The clinical procedures leading to the removal of a tumour include marking the lesion for location during surgery. The current standard of care for breast tumours is for a hooked guide wire to be fixed into the tumour. The tail of the guide wire protrudes from the breast and is taped to the patient, and the surgeon can later follow the wire to remove the tumour and along with a margin of healthy tissue.

If the guide wire moves in between implantation and surgery, it could result in the patient requiring additional surgery to correctly remove a safe margin of healthy tissue. This movement can also lead to the removal of more tissue than desired. In addition, due to the open incision created by the guide wire, surgery must be performed on the same day, creating workflow challenges for the hospital.

Many hospitals are now implementing radioactive seeds to replace the breast guide wire. This technique considerably reduces the incidence of additional surgery and removal of excess margin for the patient. The seeds also increase the time between lesion marking and surgery improving workflow, but they introduce new challenges regarding the ‘chain of custody’ for managing radioactive materials.

Endomag has developed a magnetic lesion marker (metallic pellet) for breast cancer called Magseed. Magseed works in conjunction with the Sentimag to maintain the benefits of radioactive seeds, but avoiding their challenges. Sentimag and Magseed have FDA 510(k) clearance and are available in the United States.


Posted in Magseed-En by ادمین

Leave a Comment

Powered by